Merck and Moderna maintain a decade-old collaborative agreement on their personalized mRNA cancer vaccine, recently bolstered by positive Phase 3 INTerpath-001 results in August 2026 that met recurrence-free and distant metastasis-free survival endpoints in high-risk melanoma. This success has driven independent share price gains without triggering acquisition signals, regulatory filings, or credible merger rumors. Merck has pursued separate deals, including the Terns Pharmaceuticals acquisition, while facing its own Keytruda patent pressures. With no disclosed M&A discussions, board activity, or antitrust considerations as of mid-September 2026, trader consensus assigns an 85.7% implied probability to no announcement this year, reflecting the stability of the existing 50/50 economics over full integration.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui12% peluang
BARU
BARU
Dec 31, 2026
12% peluang
BARU
BARU
Dec 31, 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a decade-old collaborative agreement on their personalized mRNA cancer vaccine, recently bolstered by positive Phase 3 INTerpath-001 results in August 2026 that met recurrence-free and distant metastasis-free survival endpoints in high-risk melanoma. This success has driven independent share price gains without triggering acquisition signals, regulatory filings, or credible merger rumors. Merck has pursued separate deals, including the Terns Pharmaceuticals acquisition, while facing its own Keytruda patent pressures. With no disclosed M&A discussions, board activity, or antitrust considerations as of mid-September 2026, trader consensus assigns an 85.7% implied probability to no announcement this year, reflecting the stability of the existing 50/50 economics over full integration.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Pasar Dibuka: Aug 19, 2026, 3:58 PM ET
Volume
$467Tanggal Berakhir
Jan 1, 2027Pasar Dibuka
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a decade-old collaborative agreement on their personalized mRNA cancer vaccine, recently bolstered by positive Phase 3 INTerpath-001 results in August 2026 that met recurrence-free and distant metastasis-free survival endpoints in high-risk melanoma. This success has driven independent share price gains without triggering acquisition signals, regulatory filings, or credible merger rumors. Merck has pursued separate deals, including the Terns Pharmaceuticals acquisition, while facing its own Keytruda patent pressures. With no disclosed M&A discussions, board activity, or antitrust considerations as of mid-September 2026, trader consensus assigns an 85.7% implied probability to no announcement this year, reflecting the stability of the existing 50/50 economics over full integration.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Volume
$467Tanggal Berakhir
Jan 1, 2027Pasar Dibuka
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Merck and Moderna maintain a decade-old collaborative agreement on their personalized mRNA cancer vaccine, recently bolstered by positive Phase 3 INTerpath-001 results in August 2026 that met recurrence-free and distant metastasis-free survival endpoints in high-risk melanoma. This success has driven independent share price gains without triggering acquisition signals, regulatory filings, or credible merger rumors. Merck has pursued separate deals, including the Terns Pharmaceuticals acquisition, while facing its own Keytruda patent pressures. With no disclosed M&A discussions, board activity, or antitrust considerations as of mid-September 2026, trader consensus assigns an 85.7% implied probability to no announcement this year, reflecting the stability of the existing 50/50 economics over full integration.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui
Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan